Veterinary Orthobiologics Market to Grow with a CAGR of 8.15% through 2029

Rising Incidence of Musculoskeletal Disorders and Increasing Pet Ownership and Humanization of Pets are expected to drive the Global Veterinary Orthobiologics Market growth in the forecast period, 2025-2029

According to TechSci Research report, “Veterinary Orthobiologics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Veterinary Orthobiologics Market stood at USD 689.85 Million in 2023 and is anticipated to grow with a CAGR of 8.15% in the forecast period through 2029.

The proliferation of veterinary clinics, especially those specializing in orthopedics and regenerative medicine, is a major growth driver. The increasing number of clinics offering orthobiologic treatments enhances accessibility and meets the rising demand for these advanced therapies. The establishment of specialized veterinary practices, which focus on musculoskeletal conditions and regenerative medicine, further supports market growth. These clinics, equipped with state-of-the-art technologies and expert knowledge, promote the use of cutting-edge orthobiologic therapies, thus broadening the scope of treatment options available. Also, the integration of advanced training programs into veterinary education plays a crucial role in driving market expansion. Veterinary schools and professional organizations are increasingly offering specialized training and continuing education on orthobiologic treatments. This education ensures that veterinarians are well-informed about the latest advancements and techniques, facilitating the adoption of innovative therapies and contributing to market growth.

Investments in research and development are also pivotal in advancing the veterinary orthobiologics market. Increased funding from pharmaceutical companies, biotechnology firms, and research institutions drives innovation in orthobiologic products. These R&D efforts focus on enhancing existing therapies, developing new products, and validating their effectiveness, which collectively fuels market expansion. Collaborative research initiatives involving industry players, academic institutions, and veterinary professionals foster innovation and accelerate the development of novel orthobiologic therapies. These partnerships enhance the research pipeline and expedite the introduction of advanced treatments to the market.

Also, clinical trials and validation studies are essential for demonstrating the safety and efficacy of orthobiologic treatments. Positive outcomes from these studies support the adoption of new therapies and provide evidence-based benefits to veterinarians and pet owners, thereby driving market growth.

The growth of the global veterinary orthobiologics market is propelled by a combination of factors. The increasing prevalence of musculoskeletal disorders, advancements in regenerative medicine technology, rising pet ownership and humanization trends, expansion of veterinary practices, and substantial investments in research and development all contribute to the market's expansion. These drivers collectively enhance the adoption of orthobiologic therapies in veterinary medicine, reflecting a dynamic and evolving sector poised for continued growth.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Veterinary Orthobiologics Market”

The Global Veterinary Orthobiologics Market is segmented into product, animal, application, delivery mode, end user, regional distribution, and company.

Based on delivery mode, the intra-articular delivery segment has emerged as the predominant market leader, Intra-articular delivery ensures that the therapeutic agents, such as platelet-rich plasma (PRP) or stem cells, are administered directly to the site of injury or degeneration. This direct application enhances the efficacy of the treatment by focusing the therapeutic agents where they are needed most, leading to more effective management of joint-related conditions. By delivering the orthobiologic agents directly into the joint, the concentration of the therapeutic substance at the target site is significantly higher compared to systemic administration. This localized high concentration enhances the treatment’s ability to promote healing, reduce inflammation, and alleviate pain more effectively. Intra-articular delivery is particularly effective in addressing symptoms associated with joint disorders, such as pain and stiffness. By targeting the joint space, this method provides more immediate and pronounced relief from symptoms, which contributes to its preference among veterinarians and pet owners. Treatments administered via intra-articular delivery can offer longer-lasting benefits compared to other delivery methods. The direct application allows for a sustained therapeutic effect, as the agents remain concentrated in the joint space for extended periods, promoting ongoing joint health and functionality. One of the key advantages of intra-articular delivery is the reduction in systemic exposure to therapeutic agents. By delivering the treatment directly into the joint, the risk of systemic side effects is minimized, making it a safer option for animals who may be sensitive to systemic medications. The targeted nature of intra-articular delivery ensures that the therapeutic agents act specifically on the joint, reducing the likelihood of unintended effects on other parts of the body. This targeted action enhances the overall safety profile of the treatment.

The Europe region is experiencing rapid market growth. Europe boasts a well-established and sophisticated veterinary healthcare infrastructure. The presence of numerous advanced veterinary clinics and specialized centers, particularly those focusing on orthopedics and regenerative medicine, supports the rapid adoption of innovative orthobiologic treatments. These facilities are equipped with cutting-edge technology and have a high level of expertise in managing complex musculoskeletal disorders. European countries are known for their high standards of veterinary care and commitment to animal welfare. This regulatory and practice environment fosters the integration of advanced therapeutic options, such as orthobiologics, which are increasingly sought after for their efficacy in treating a range of musculoskeletal conditions.

There is a rising prevalence of musculoskeletal disorders in both companion animals and livestock across Europe. This increase in incidence drives demand for effective and innovative treatment options, including orthobiologics, to address conditions such as arthritis, ligament injuries, and degenerative joint diseases. The trend of pet humanization and the growing number of pet owners in Europe contribute to increased expenditure on veterinary care. Pet owners are increasingly seeking advanced treatments for their animals, including orthobiologics, to ensure optimal health and quality of life for their pets. Europe has a relatively supportive regulatory framework for the approval and commercialization of veterinary products, including orthobiologics. The European Medicines Agency (EMA) and national regulatory bodies facilitate the approval process for new treatments, which accelerates market entry and growth. The European Union’s efforts to harmonize standards and regulations across member states streamline the introduction of innovative veterinary products. This regulatory alignment helps companies navigate the market more efficiently and ensures consistent product quality and safety standards.

Major companies operating in Global Veterinary Orthobiologics Market are:

• Zoetis Services LLC
• Boehringer Ingelheim International GmbH
• Ardent Animal Health
• Enso Discoveries, LLC
• VetStem, Inc
• MEDREGO LLC
• Arthrex, Inc.
• Hilltop Biosciences
• Enovis Corporation
• Dechra Pharmaceuticals Limited

Download Free Sample Report

Customers can also request for 10% free customization on this report

“Global Veterinary Orthobiologics market is poised for significant growth, driven by a range of dynamic factors. The increasing prevalence of musculoskeletal disorders, coupled with advancements in regenerative medicine and rising pet ownership, creates a robust demand for innovative orthobiologic treatments. The expansion of specialized veterinary practices, supportive regulatory frameworks, and substantial investments in research and development further fuel this growth. As technological innovations continue to enhance treatment efficacy and accessibility, and as market players increasingly focus on addressing the needs of both companion animals and livestock, the veterinary orthobiologics sector is set to experience robust expansion and evolving opportunities. This progress underscores a promising future for the market, with ongoing developments poised to deliver advanced therapeutic solutions and improve animal health outcomes worldwide.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Veterinary Orthobiologics Market – Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product (Stem Cells, Platelet-rich Plasma (PRP), Other), By Animal (Canine, Equine, Others), By Application (Osteoarthritis, Degenerative Joint Disease, Other), By Delivery Mode (Intra-muscular/Intra-lesional, Intra-articular, Others), By End User (Veterinary Hospitals, Veterinary Clinics, Others), By Region & Competition, 2019-2029F”, has evaluated the future growth potential of Global Veterinary Orthobiologics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Veterinary Orthobiologics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]